← Leaderboards
Tobey J Macdonald
Children'S Research Institute
$1,954,906
Attributed
$1,954,906
Total exposure
18
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $396.1K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$1,954,906 · 18
By mechanism
R01$1,278,098 · 1
K08$635,904 · 1
M01$40,904 · 16
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pediatric Neoplasm /Cancer”
- Gregory H Reaman · National Childhood Cancer Foundation$143,691,240
- Steven Terry Rosen · Beckman Research Institute/City Of Hope$22,909,759
- Leland H Hartwell · Fred Hutchinson Cancer Research Center$22,238,492
- W. Archie Bleyer · National Childhood Cancer Foundation$13,947,311
- Richard Sposto · Epicenter Software$12,526,922
- Cheryl L Willman · University Of New Mexico$11,717,785
Research focus
Pediatric Neoplasm /CancerNeoplasm /Cancer ChemotherapyClinical Trial Phase IDrug Screening /EvaluationDoseResearch PersonnelChildMedulloblastomaNeoplastic CellGene ExpressionResponseTumorPhosphorylationMitogen Activated Protein KinaseInstitutionAthymic MouseComputer Retrieval Of Information On Scientific Projects DatabaseMalignant GliomaApoptosisHuman SubjectAntineoplasticsBrain Stem GliomaGrantHuman Therapy Evaluation
Grant awards (26)
The Role of PDGFR in Medulloblastoma Progression$240,431
R01 · FY2010 · CA · contact PI
The Role of PDGFR in Medulloblastoma Progression$257,494
R01 · FY2009 · CA · contact PI
The Role of PDGFR in Medulloblastoma Progression$257,494
R01 · FY2008 · CA · contact PI
PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTORSAR) IN CHILDREN WITH RECR$4,791
M01 · FY2008 · RR · contact PI
PBTC 007 V10B- A PHASE I/II TRIAL OF ZD 1839 (IRESSA)$684
M01 · FY2008 · RR · contact PI
The Role of PDGFR in Medulloblastoma Progression$257,494
R01 · FY2007 · CA · contact PI
PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTORSAR) IN CHILDREN WITH RECR$2,224
M01 · FY2007 · RR · contact PI
PBTC 007 V10B- A PHASE I/II TRIAL OF ZD 1839 (IRESSA)$318
M01 · FY2007 · RR · contact PI
The Role of PDGFR in Medulloblastoma Progression$265,185
R01 · FY2006 · CA · contact PI
Regulation- Medulloblastoma Growth by alpha-v integrins$125,721
K08 · FY2006 · CA · contact PI
PBTC016: A PHASE I, MOLECULAR BIOLOGY AND PHASE II STUDY OF LAPATINIB (GW5720A$3,098
M01 · FY2006 · RR · contact PI
PBTC 007 V10B- A PHASE I/II TRIAL OF ZD 1839 (IRESSA)$1,033
M01 · FY2006 · RR · contact PI
PBTC-017: PHASE I STUDY OF CLORETAZINE (VNP40101M) IN CHILDREN WITH RECURRENT,$1,033
M01 · FY2006 · RR · contact PI
Regulation- Medulloblastoma Growth by alpha-v integrins$130,653
K08 · FY2005 · CA
PBTC 005 - PHASE I TRIAL OF TEMOZOLOMIDE &06 BENZYLGUANINE IN PEDIATRIC PATIENT$5,824
M01 · FY2005 · RR
PHASE I TRIAL OF SCH 66336 IN PED PATIENT W/ REFRACTORY OR RECURRENT BRAIN TUMOR$3,236
M01 · FY2005 · RR
PBTC009 - PHASE I TRIAL OF GLIADEL AND O6-BENZYLGUANINE$2,912
M01 · FY2005 · RR
PBTC-012: PHASE I STUDY OF CILENGIUDE (EMD 121974) IN CHILD W BRAIN TUMORS$2,912
M01 · FY2005 · RR
PBTC-006: A PHASE I/II TRIAL OF STI571 IN CHILDREN$1,616
M01 · FY2005 · RR
Regulation- Medulloblastoma Growth by alpha-v integrins$129,305
K08 · FY2004 · CA
PBTC 005v1.1 Phase I Trial of Temozolomide and O6-Benzylguanine$6,664
M01 · FY2004 · RR
A Phase I Study of Cilengitide (EMD 121974) in Pediatric Patients with Refractor$3,859
M01 · FY2004 · RR
PBTC 007 v1.0b- A Phase I/II Trial of ZD 1839 (Iressa)$350
M01 · FY2004 · RR
PBTC 003-A Phase I Trial of Escalating Oral Dose of SCH66336 in Pediatric$350
M01 · FY2004 · RR
Regulation- Medulloblastoma Growth by alpha-v integrins$126,483
K08 · FY2003 · CA
Regulation- Medulloblastoma Growth by alpha-v integrins$123,742
K08 · FY2002 · CA